Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of OX-382

Trial Profile

A phase I study of OX-382

Phase of Trial: Phase I

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jan 2018 According to an Orexo media release, trial results expected in Q2, 2018.
    • 25 Jan 2018 Status changed from planning to recruiting, according to an Orexo media release.
    • 19 Oct 2017 According to an Orexo media release, this trial is scheduled to start in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top